Ana I Esquifino

Prof. Dr. Ana I Esquifino

Department of Biochemistry and Molecular Biology of the Complutense University of Madrid (Departamental Section in Medicine Faculty), Madrid, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2005 in Immunity & Ageing
Verified
Journal Article
Open access
VSV Srinivasan
V Srinivasan
GMGjm Maestroni
Gjm Maestroni
DCDaniel Cardinali
Daniel Cardinali
Ana I EsquifinoAna I Esquifino
Ana I Esquifino
Seithikurippu R. Pandi-PerumalSeithikurippu R. Pandi-Perumal
Seithikurippu R. Pandi-Perumal
SMSc Miller
Sc Miller
Aging is associated with a decline in immune function (immunosenescence), a situation known to correlate with increased incidence of cancer, infectious and degenerative diseases. Innate, cellular and humoral immunity all exhibit increased deterioration with age. A decrease in functional competence of individual natural killer (NK) cells is found with advancing age. Macrophages and granulocytes show functional decline in aging as evidenced by their diminished phagocytic activity and impairment of superoxide generation. There is also marked shift in cytokine profile as age advances, e.g., CD3+ and CD4+ cells decline in number whereas CD8+ cells increase in elderly individuals. A decline in organ specific antibodies occurs causing reduced humoral responsiveness. Circulating melatonin decreases with age and in recent years much interest has been focused on its immunomodulatory effect. Melatonin stimulates the production of progenitor cells for granulocytes-macrophages. It also stimulates the production of NK cells and CD4+ cells and inhibits CD8+ cells. The production and release of various cytokines from NK cells and T-helper lymphocytes also are enhanced by melatonin. Melatonin presumably regulates immune function by acting on the immune-opioid network, by affecting G protein-cAMP signal pathway and by regulating intracellular glutathione levels. Melatonin has the potential therapeutic value to enhance immune function in aged individuals and in patients in an immunocompromised state.

28 March 2006 in International Journal of Experimental Pathology
Verified
Journal Article
Open access
PDF file
SMSandra C. Miller
Sandra C. Miller
Seithikurippu R. Pandi-PerumalSeithikurippu R. Pandi-Perumal
Seithikurippu R. Pandi-Perumal
Ana I EsquifinoAna I Esquifino
Ana I Esquifino
DCDaniel P. Cardinali
Daniel P. Cardinali
GMGeorges J. M. Maestroni
Georges J. M. Maestroni
Summary: Melatonin, a neurohormone produced mainly by the pineal gland, is a modulator of haemopoiesis and of immune cell production and function, both in vivo and in vitro. Physiologically, melatonin is associated with T‐helper 1 (Th1) cytokines, and its administration favours Th1 priming. In both normal and leukaemic mice, melatonin administration results in quantitative and functional enhancement of natural killer (NK) cells, whose role is to mediate defenses against virus‐infected and cancer cells. Melatonin appears to regulate cell dynamics, including the proliferative and maturational stages of virtually all haemopoietic and immune cells lineages involved in host defense – not only NK cells but also T and B lymphocytes, granulocytes and monocytes – in both bone marrow and tissues. In particular, melatonin is a powerful antiapoptotic signal promoting the survival of normal granulocytes and B lymphocytes. In mice bearing mid‐stage leukaemia, daily administration of melatonin results in a survival index of 30–40% vs. 0% in untreated mice. Thus, melatonin seems to have a fundamental role as a system regulator in haemopoiesis and immuno‐enhancement, appears to be closely involved in several fundamental aspects of host defense and has the potential to be useful as an adjuvant tumour immunotherapeutic agent.

19 July 2010 in Journal of Pineal Research
Verified
Journal Article
Open access
PDF file
MLMaría Judith Rios Lugo
María Judith Rios Lugo
PCPilar Cano-Barquilla
Pilar Cano-Barquilla
VJVanesa Jiménez‐Ortega
Vanesa Jiménez‐Ortega
PFPILAR FERNANDEZ-MATEOS
PILAR FERNANDEZ-MATEOS
PSPablo A. Scacchi
Pablo A. Scacchi
Ana I EsquifinoAna I Esquifino
Ana I Esquifino
Abstract:  Melatonin effect on body weight progression, mean levels and 24‐hr pattern of circulating adiponectin, leptin, insulin, glucose, triglycerides and cholesterol were examined in rats fed a normal or a high‐fat diet. In experiment 1, rats fed a normal diet were divided into two groups: receiving melatonin (25 μg/mL drinking water) or vehicle for 9 wk. In experiment 2, animals were divided into three groups: two fed with a high‐fat diet (35% fat) and melatonin (25 μg/mL) or vehicle in drinking water for 11 wk, while a third group was given a normal diet (4% fat). At the end of experiments, groups of eight rats were killed at six different time intervals throughout a 24‐ hr period. Melatonin administration for 9 wk decreased body weight gain from the 3rd wk on without affecting food intake. A significant reduction in circulating insulin, glucose and triglyceride mean levels and disrupted daily patterns of plasma adiponectin, leptin and insulin were observed after melatonin. In high fat–fed rats, melatonin attenuated body weight increase, hyperglycemia and hyperinsulinemia, as well as the increase in mean plasma adiponectin, leptin, triglycerides and cholesterol levels. The high‐fat diet disrupted normal 24‐ hr patterns of circulating adiponectin, insulin and cholesterol, the effects on insulin and cholesterol being counteracted by melatonin. Nocturnal plasma melatonin concentration in control and obese rats receiving melatonin for 11 wk attained values 21–24‐fold greater than controls. The results indicate that melatonin counteracts some of the disrupting effects of diet‐induced obesity in rats.

1 November 2008 in Neuroimmunomodulation
Verified
Journal Article
Closed access
PDF file
DCDaniel P. Cardinali
Daniel P. Cardinali
Ana I EsquifinoAna I Esquifino
Ana I Esquifino
VSVenkataramanujan Srinivasan
Venkataramanujan Srinivasan
Seithikurippu R. Pandi-PerumalSeithikurippu R. Pandi-Perumal
Seithikurippu R. Pandi-Perumal
Aging is associated with a decline in immune function (immunosenescence), a condition known to correlate with increased incidence of cancer as well as infectious and degenerative diseases. Innate, cellular and humoral immunity all exhibit increased deterioration with age. Circulating melatonin decreases with age, and in recent years much interest has been focused on its immunomodulatory effect. Melatonin stimulates the production of progenitor cells for granulocytes and macrophages. It also stimulates the production of natural killer cells and CD4+ cells and inhibits CD8+ cells. The production and release of various cytokines from natural killer cells and T helper lymphocytes are enhanced by melatonin. Melatonin has the potential therapeutic value to enhance immune function in aged individuals.

1 April 2008 in Endocrine
Verified
Journal Article
Closed access
PDF file
PCPilar Cano-Barquilla
Pilar Cano-Barquilla
VJVanesa Jiménez-Ortega
Vanesa Jiménez-Ortega
ÁLÁlvaro Larrad
Álvaro Larrad
CTCarlos F. Reyes Toso
Carlos F. Reyes Toso
DCDaniel P. Cardinali
Daniel P. Cardinali
Ana I EsquifinoAna I Esquifino
Ana I Esquifino